Evidence map›Paper›PMID 41880107›Full record

ArticleBioresources and bioprocessing2026

Engineering of Corynebacterium glutamicum for the enhanced production of optically pure (meso)-2,3-butanediol.

Eun Seo Song, Kyeong Ho Kim, Joon Young Lee, Ki Jun Jeong

Abstract read
In one paragraph

Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eun Seo SongGraduate School of Engineering Biology, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea.
Kyeong Ho KimDepartment of Chemical and Biomolecular Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea.
Joon Young LeeDepartment of Chemical and Biomolecular Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea.
Ki Jun JeongGraduate School of Engineering Biology, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea. kjjeong@kaist.ac.kr.ORCID http://orcid.org/0000-0002-9432-7519

Funding

National Research Foundation of Korea RS-2025-02214232National Research Foundation of Korea RS-2025-02215308
6 · The paper itself

Abstract

2,3-Butanediol (2,3-BDO) is a versatile platform chemical with diverse applications in cosmetics, pharmaceuticals, agricultural and food manufacturing. Among its stereoisomers, optically pure (meso)-2,3-BDO is particularly valuable; however, achieving high titers with stereoselectivity remains challenging in conventional hosts due to byproduct formation, low tolerance, and plasmid instability. In this study, we established Corynebacterium glutamicum as an efficient and robust chassis for the industrial-level production of optically pure (meso)-2,3-BDO. A structure-guided engineering approach was applied to 2,3-butanediol dehydrogenase (KpBDH), where α6-helix truncation enhanced catalytic efficiency and enabled near-complete conversion of acetoin to the target isomer. To further improve productivity, competing byproduct pathways were deleted, and cofactor homeostasis was reinforced by integrating UdhA for NADH regeneration and DrPPK for ATP regeneration. Finally, all biosynthetic modules were stably integrated into the chromosome, generating the plasmid-free strain ES11. In 5L fed-batch fermentation, ES11 produced 100.4 ± 0.4 g/L (meso)-2,3-BDO with > 99% optical purity, a yield of 0.33 ± 0.04 g/g glucose, and productivity of 0.82 ± 0.06 g/L/h. This work represents the first demonstration of > 100 g/L optically pure (meso)-2,3-BDO using C. glutamicum and establishes an integrated strategy of enzyme engineering, pathway optimization, and process design.

Indexed as

Corynebacterium glutamicumEnzyme engineering(meso)-2,3-butanediolMetabolic engineeringPlasmid-free biomanufacturing

Identifiers

PMID41880107
PMCPMC13018514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.